<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833937</url>
  </required_header>
  <id_info>
    <org_study_id>B016540</org_study_id>
    <nct_id>NCT00833937</nct_id>
  </id_info>
  <brief_title>Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bioavailability of Zolpidem tartrate&#xD;
      10 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA&#xD;
      Pharmaceuticals USA) with that of AMBIEN® tablets(G.D. Searle &amp; Co.) in healthy, adult,&#xD;
      non-smoking subjects under non-fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambien®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem 10 mg tablets</intervention_name>
    <description>1 x 10 mg</description>
    <arm_group_label>Zolpidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMBIEN® 10 mg tablets</intervention_name>
    <description>1 x 10 mg</description>
    <arm_group_label>Ambien®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects selected for this study will be non-smokers at least 18 years of age.&#xD;
             Subjects will have a BMI (body mass index) of 30 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a significant recent history of chronic alcohol consumption, drug&#xD;
             addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease,&#xD;
             tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible&#xD;
             for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal&#xD;
             range may be retested. If the clinical values are outside the range on retesting, the&#xD;
             subject will not be eligible to participate in the study unless the clinical&#xD;
             investigator deems the result to not be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic responses to the class of drug being tested&#xD;
             will be excluded from the study.&#xD;
&#xD;
          -  Subjects who use tobacco in any form will not be eligible to participate in the study.&#xD;
             Three months abstinence is required.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as&#xD;
             part of the clinical laboratory screening procedures and at each dosing period&#xD;
             check-in. Subjects found to have urine concentrations of any of the tested drugs will&#xD;
             not be allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/or plasma for at least thirty (30) days&#xD;
             prior to the first dosing of the study.&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within thirty (30) days prior to the&#xD;
             first dosing of the study will not be allowed to participate.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant&#xD;
             during the study will not be allowed to participate. Female subjects of child bearing&#xD;
             potential must either abstain from sexual intercourse or use a reliable barrier method&#xD;
             (e.g. condom, IUD) of contraception during the course of the study (first dosing until&#xD;
             last blood collection) or they will not be allowed to participate. Subjects who have&#xD;
             used implanted or injected hormonal contraceptives anytime during the 180 days prior&#xD;
             to study dosing or oral hormonal contraceptives with in 14 days of dosing will not be&#xD;
             allowed to participate.&#xD;
&#xD;
          -  All Female subjects will be screened for pregnancy at check-in each study period.&#xD;
             Subjects with positive or inconclusive results will be withdrawn from the study.&#xD;
&#xD;
          -  Subjects who do not tolerate venipuncture will not be allowed to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirley Ann Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novum Pharmaceuticals Research Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novum Pharmaceutical Research Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioassay Laboratory, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2009</study_first_posted>
  <results_first_submitted>July 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zolpidem (Test) First</title>
          <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Ambien® (Reference) First</title>
          <description>Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zolpidem (Test) First</title>
          <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Ambien® (Reference) First</title>
          <description>Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Ambien®</title>
            <description>Ambien® 10 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.313" spread="42.878"/>
                    <measurement group_id="O2" value="116.452" spread="40.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>99.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.9</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Ambien®</title>
            <description>Ambien® 10 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541.580" spread="279.254"/>
                    <measurement group_id="O2" value="543.732" spread="273.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>97.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.6</ci_lower_limit>
            <ci_upper_limit>103</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>Zolpidem Tartrate 10 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Ambien®</title>
            <description>Ambien® 10 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530.272" spread="271.461"/>
                    <measurement group_id="O2" value="531.866" spread="265.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>97.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.7</ci_lower_limit>
            <ci_upper_limit>103</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

